RecruitingNot ApplicableNCT07012148

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

FORESITE (FOREcasting Seizures to Initiate ThErapy): Optimizing Management of Drug-Resistant Epilepsy Using Seizure Forecasts Via Subscalp EEG and Wearables

Sponsor

Mayo Clinic

Enrollment

12 participants

Start Date

Jan 20, 2026

Study Type

INTERVENTIONAL

Conditions

Focal Epilepsy Generalized Seizure Drug Refractory Epilepsy

Summary

The purpose of this study is to evaluate the safety and feasibility of using seizure forecasts based on subscalp EEG.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying UNEEG SubQ device for people with drug refractory epilepsy, focal epilepsy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEUNEEG SubQ device

Subjects will be implanted with the UNEEG SubQ device in the neurosurgical operating suite under general anesthesia. Electrodes will be placed over the temporal lobe of the hemisphere established as the origin of seizures by previous EEG monitoring. Only one UNEEG device will be placed, and only the seizure onset hemisphere will be covered.